- Home
- IONS vs FNB Comparison
IONS vs FNB Comparison
Compare IONS & FNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- FNB
- Stock Information
- Founded
- IONS 1989
- FNB 1864
- Country
- IONS United States
- FNB United States
- Employees
- IONS N/A
- FNB N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- FNB Major Banks
- Sector
- IONS Health Care
- FNB Finance
- Exchange
- IONS Nasdaq
- FNB Nasdaq
- Market Cap
- IONS 4.6B
- FNB 4.8B
- IPO Year
- IONS 1991
- FNB N/A
- Fundamental
- Price
- IONS $32.26
- FNB $13.65
- Analyst Decision
- IONS Buy
- FNB Strong Buy
- Analyst Count
- IONS 18
- FNB 7
- Target Price
- IONS $57.41
- FNB $18.07
- AVG Volume (30 Days)
- IONS 1.7M
- FNB 3.0M
- Earning Date
- IONS 04-30-2025
- FNB 04-16-2025
- Dividend Yield
- IONS N/A
- FNB 3.51%
- EPS Growth
- IONS N/A
- FNB 3.29
- EPS
- IONS N/A
- FNB 1.27
- Revenue
- IONS $717,253,000.00
- FNB $1,517,042,000.00
- Revenue This Year
- IONS N/A
- FNB $14.98
- Revenue Next Year
- IONS $27.39
- FNB $9.87
- P/E Ratio
- IONS N/A
- FNB $10.77
- Revenue Growth
- IONS N/A
- FNB 1.81
- 52 Week Low
- IONS $23.95
- FNB $10.88
- 52 Week High
- IONS $52.34
- FNB $17.70
- Technical
- Relative Strength Index (RSI)
- IONS 57.55
- FNB 59.60
- Support Level
- IONS $31.66
- FNB $13.38
- Resistance Level
- IONS $33.98
- FNB $13.92
- Average True Range (ATR)
- IONS 1.30
- FNB 0.33
- MACD
- IONS 0.41
- FNB 0.12
- Stochastic Oscillator
- IONS 68.84
- FNB 89.78
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About FNB F.N.B. Corporation
F N B Corp provides a full range of financial services, principally to consumers, corporations, governments and small- to medium-sized businesses. It has three reportable business segments: Community Banking, Wealth Management and Insurance. The majority of revenue is from the Community banking segment. It offers commercial & consumer banking services. Commercial banking solutions include corporate banking, small business banking, investment real estate financing, business credit, capital markets & lease financing. Consumer banking products & services include deposit products, mortgage lending, & consumer lending & a complete suite of mobile & online banking services.